Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Tacrolimus in Vernal Keratoconjunctivitis
NCT02456025Phase 4Unknown
- Sponsor
- The Eye Center and The Eye Foundation for Research in Ophthalmology
- Start
- Apr 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Tacrolimus Ointment 0.1% Iwaki in Vernal Keratoconjunctivitis (VKC), sponsored by The Eye Center and The Eye Foundation for Research in Ophthalmology. Primary endpoints: Efficacy of Topical Tacrolimus in Vernal Keratoconjunctivitis at 5 months and Graded Itching Symptom at 1 month. Status: unknown.
02
Drugs
Tacrolimus Ointment 0.1% Iwaki
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on NCT02456025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02456025.